[Response to intracavernous administration of 3 different drugs in the same group of patients with erectile dysfunction].

Abstract

OBJECTIVE:

To compare the subjective and objective penile rigidity in the same group of patients with erectile dysfunction after intracavernous injection of different vasoactive drugs.

METHODS:

91 impotent males were randomly assigned to three groups of intracavernous injection: A: 20 micrograms PGE1 B: 30 mg papaverine hydrochloride + 1 mg phentolamine (bimix), and C: 10 micrograms PGE1 + 15 mg papaverine hydrochloride + 0.5 mg phentolamine (trimix). Each patient was scheduled to receive the three modalities of intracavernous injection randomly with an interval of 7-10 days between injections. Penile rigidity equal to or more than 60% was considered positive. Subjective and objective penile rigidity were evaluated with callipers by the same observer.

RESULTS:

82 patients completed the study and 9 dropped out after prolonged erection with one of the ICI modalities. Rigidity after treatment with C (66 +/- 15%) was significantly superior to that of B (59 +/- 15%, p = 0.0001) and A (60 +/- 13%, p = 0.0115). No differences were observed between A and B (p = 0.4644). Analysis of only the positive response showed significant differences between A and C, but not between C and B (p = 0.3323). Differences were not found between the response to PGE1 (A) and bimix (B) (p = 0.1275). The order of application of the drug had no effect on response (p = 0.026).

CONCLUSIONS:

A higher percentage of positive response in patients with erectile dysfunction was achieved with the trimix modality. Choice of more potent ICI regimens can improve the diagnostic and/or therapeutic efficacy in males that do not respond to PGE1 alone.

• Authors: N Ribé, O Rajmil, L Bassas, C Jurado, J M Pomerol
• Journal: Archivos espanoles de urologia (Arch Esp Urol) Vol. 54 Issue 4 Pg. 355-9 (May 2001) ISSN: 0004-0614 [Print] Spain
• Vernacular Title: Respuesta a la administración intracavernosa de tres fármacos diferentes en el mismo grupo de pacientes con disfunción eréctil.
• PMID: 11455770 (Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Adrenergic alpha-Antagonists
• Vasodilator Agents
• Papaverine
• Alprostadil
• Phentolamine

Topics

• Adrenergic alpha-Antagonists (administration & dosage)
• Alprostadil (administration & dosage)
• Erectile Dysfunction (drug therapy)
• Humans
• Injections
• Male
• Papaverine (administration & dosage)
• Penis
• Phentolamine (administration & dosage)
• Vasodilator Agents (administration & dosage)